Evidence map›Paper›PMID 40346429›Full record

ArticlePsychopharmacology2025

Chronic administration of methocinnamox, a mu-opioid receptor antagonist, reduces hedonic response without impacting motivation in mice.

Misbah Sheikh, Emily Cambre, Cory Langreck, Jonathan A Javitch, Sarah E Canetta

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Misbah SheikhDepartment of Neuroscience, Barnard College, New York, NY, USA.
Emily CambreDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Cory LangreckDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Jonathan A JavitchDepartment of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, NY, USA.
Sarah E CanettaDivision of Developmental Neuroscience, Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA. ses2119@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-3860-2504

Funding

Hope for Depression Research Foundation Hope for Depression Research FoundationIrving Institute Columbia University TL1 Predoctoral Training AwardNIMH NIH HHS R01MH128277-01Research Foundation for Mental Hygiene Director's Pilot Award
6 · The paper itself

Abstract

rationaleGenetic and pharmacological studies suggest that signaling through the mu opioid receptor (MOR) is essential for motivation to seek, and hedonic response to, both drugs of abuse as well as natural rewards. Given that impairments in hedonic reactivity and motivation are key behavioral features of depression, we wondered whether sustained deficits in endogenous opioid signaling in adulthood could produce these 'depression-related' behavioral phenotypes.

objectivesTo investigate the effect of chronic MOR blockade in adulthood on motivation and hedonic response to a food reward, as well as whether these behavioral variables are correlated at the individual animal level.

methodsWe chronically administered the pseudo-irreversible MOR antagonist methocinnamox (MCAM) for three weeks prior to assessing motivation and hedonic reactivity for a food reward in the progressive ratio and lickometer tasks, respectively. We then assessed whether motivation and hedonic response to reward were correlated at the individual animal level.

resultsChronic administration of MCAM decreased hedonic response, while leaving goal-directed motivation intact. In addition, there was a weak negative correlation between motivation and hedonic response in individual mice treated with chronic MCAM, but not control mice.

conclusionsChronic blockade of the MOR decreases hedonic response, without impacting motivation to work for the same reward. Although the different components of reward processing such as motivation and hedonic response may be related, they appear to be dissociable.

Indexed as

MotivationNarcotic AntagonistsReceptors, Opioid, muAnimalsBehavior, AnimalMaleMiceMice, Inbred C57BLRewardNarcotic AntagonistsReceptors, Opioid, muHedonic responseLickometerMotivationMu-opioid receptorProgressive ratio

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.